M. Londei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
M. Londei has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A. Picarelli
Dept of Pediatrics, University Federico II, Naples,Italy; Dept of Gastroenterology *University La Sapienza, Rome and $University Federico II, Naples, Italy; ¶Kennedy Institute of Rheumatology London UK
2 shared publications- Giovanni de Marco
Dermatology Unit, NESMOS Department, S. Andrea Hospital, University of Rome "Sapienza
2 shared publications L. Maiuri
Dept of Pediatrics, University Federico II, Naples,Italy; Dept of Gastroenterology *University La Sapienza, Rome and $University Federico II, Naples, Italy; ¶Kennedy Institute of Rheumatology London UK
2 shared publicationsS. Auricchio
Dept of Pediatrics, University Federico II, Naples,Italy; Dept of Gastroenterology *University La Sapienza, Rome and $University Federico II, Naples, Italy; ¶Kennedy Institute of Rheumatology London UK
2 shared publicationsA. Trecca
Dept of Pediatrics, University Federico II, Naples,Italy; Dept of Gastroenterology *University La Sapienza, Rome and $University Federico II, Naples, Italy; ¶Kennedy Institute of Rheumatology London UK
1 shared publicationC. Ciacci
Dept of Pediatrics, University Federico II, Naples,Italy; Dept of Gastroenterology *University La Sapienza, Rome and $University Federico II, Naples, Italy; ¶Kennedy Institute of Rheumatology London UK
1 shared publication
Latest Publications
- 1 May 2003
- Published by Springer Nature in Gene Therapy
- Vol. 10 (10) , 835-843
Celiac Disease: a model autoimmune disease with gene therapy applications
Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.
- 1 May 2003
- Published by Springer Nature in Gene Therapy
- Vol. 10 (10) , 835-843
Celiac Disease: a model autoimmune disease with gene therapy applications
Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.
- 1 May 1998
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 26 (5) , 556
FAS AND FAS-LIGAND CO-EXPRESSION BY SMALL INTESTINE EPITHELIAL CELLS OF CELIAC PATIENTS.
- 1 May 1998
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 26 (5) , 556
FAS AND FAS-LIGAND CO-EXPRESSION BY SMALL INTESTINE EPITHELIAL CELLS OF CELIAC PATIENTS.
- 1 April 1997
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 24 (4) , 452
IL15 IS ABLE TO INDUCE MIGRATION OF CD3+CD8+ AND γ/δ+ T CELLS TO THE SURFACE EPITHELIUM IN COELIAC SMALL INTESTINAL MUCOSA
- 1 April 1997
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 24 (4) , 452
IL15 IS ABLE TO INDUCE MIGRATION OF CD3+CD8+ AND γ/δ+ T CELLS TO THE SURFACE EPITHELIUM IN COELIAC SMALL INTESTINAL MUCOSA